Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $54.97 million for the quarter.
Esperion Therapeutics Stock Up 10.8 %
NASDAQ ESPR traded up $0.11 during trading hours on Friday, hitting $1.09. The company's stock had a trading volume of 5,542,466 shares, compared to its average volume of 5,675,874. The stock has a fifty day moving average of $1.31 and a 200 day moving average of $1.92. Esperion Therapeutics has a twelve month low of $0.82 and a twelve month high of $3.94. The firm has a market capitalization of $215.98 million, a P/E ratio of -1.70 and a beta of 0.75.
Wall Street Analyst Weigh In
ESPR has been the subject of a number of research reports. JMP Securities reiterated a "market outperform" rating and set a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Needham & Company LLC reiterated a "buy" rating and set a $5.00 price objective on shares of Esperion Therapeutics in a research note on Friday, April 25th. HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research note on Friday, April 25th. Finally, The Goldman Sachs Group dropped their price target on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $6.42.
View Our Latest Analysis on Esperion Therapeutics
Esperion Therapeutics Company Profile
(
Get Free Report)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Recommended Stories
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
